- Home
- INBX vs FULC Comparison
INBX vs FULC Comparison
Compare INBX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- FULC
- Stock Information
- Founded
- INBX 2010
- FULC 2015
- Country
- INBX United States
- FULC United States
- Employees
- INBX N/A
- FULC N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- FULC Health Care
- Exchange
- INBX Nasdaq
- FULC Nasdaq
- Market Cap
- INBX 430.2M
- FULC 469.0M
- IPO Year
- INBX 2020
- FULC 2019
- Fundamental
- Price
- INBX $78.51
- FULC $8.60
- Analyst Decision
- INBX Hold
- FULC Buy
- Analyst Count
- INBX 2
- FULC 7
- Target Price
- INBX N/A
- FULC $10.43
- AVG Volume (30 Days)
- INBX 680.2K
- FULC 562.0K
- Earning Date
- INBX 11-14-2025
- FULC 10-29-2025
- Dividend Yield
- INBX N/A
- FULC N/A
- EPS Growth
- INBX N/A
- FULC N/A
- EPS
- INBX N/A
- FULC N/A
- Revenue
- INBX $1,400,000.00
- FULC N/A
- Revenue This Year
- INBX $563.00
- FULC N/A
- Revenue Next Year
- INBX $230.77
- FULC N/A
- P/E Ratio
- INBX N/A
- FULC N/A
- Revenue Growth
- INBX N/A
- FULC 2752.05
- 52 Week Low
- INBX $10.81
- FULC $2.32
- 52 Week High
- INBX $83.78
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- INBX 84.62
- FULC 46.61
- Support Level
- INBX $28.16
- FULC $8.29
- Resistance Level
- INBX $39.27
- FULC $10.09
- Average True Range (ATR)
- INBX 5.72
- FULC 0.76
- MACD
- INBX 4.49
- FULC -0.10
- Stochastic Oscillator
- INBX 90.52
- FULC 17.22
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.